Director – Global CRM Business Strategy & Enablement

Responsibilities

• Define and lead the enterprise CRM strategy and roadmap to align with customer experience goals and digital data strategy.
• Drive business ownership of CRM tools, including Veeva and Salesforce, ensuring adoption, governance, and omnichannel integration.
• Partner with Business Units, Commercial IT, and Analytics teams to ensure CRM capabilities support unique therapeutic area needs.
• Optimize HCP and patient engagement through advanced segmentation, next-best-action logic, and closed-loop measurement.
• Collaborate with IT to define business requirements, manage system scalability, and oversee CRM upgrades and integrations.
• Enhance field enablement by optimizing role-based dashboards, workflows, and usability for field representatives.
• Monitor key CRM metrics and analyze data to provide actionable insights for strategic and operational decision-making.

Requirements

• Bachelor's degree in Business Administration, Marketing, Information Systems, or a related field (MBA preferred).
• 10+ years of experience in CRM strategy development or management within the biotech/pharmaceutical industry.
• Proven expertise with Veeva and Salesforce at an enterprise level for configuration and optimization.
• Experience integrating CRM with marketing automation tools such as Salesforce Marketing Cloud or Marketo.
• Strong understanding of life sciences CRM use cases, commercial workflows, and customer lifecycle management.
• Exceptional communication and analytical skills to collaborate across matrixed Sales, Marketing, and IT organizations.

Preferred Qualifications

• Familiarity with rare disease therapeutic areas or specialty pharma marketing practices.
• Experience managing complex system integrations or global Veeva and Salesforce implementations.

About the Company

BioMarin is a global biotechnology company that relentlessly pursues bold science to translate genetic discoveries into new medicines that advance the future of human health. Since 1997, we have applied our scientific expertise to create transformative medicines for patients with significant unmet medical needs.